Preview

Научно-практическая ревматология

Расширенный поиск

Особенности болезни Стилла, развившейся у взрослых, в XXI в.

https://doi.org/10.14412/1995-4484-2018-506-514

Полный текст:

Аннотация

В обзоре представлены современные данные о болезни Стилла, развившейся у взрослых: причинах ее возникновения, особенностях патогенеза, диагностики, клинической картины (с выделением субтипов), лечения с учетом характера течения и угрожающих жизни осложнений.

Об авторах

В. В. Лебедева
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой»
Россия


Ю. В. Муравьев
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой»
Россия


Список литературы

1. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60 (Reprinted in: Arch Dis Child. 1941;16:156-65). doi: 10.1136/adc.16.87.156

2. Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30:121-33. doi: 10.1136/ard.30.2.121

3. Tanaka S, Matsumoto Y, Ohnishi H, et al. [Comparison of clinical features of childhood and adult onset Still’s disease]. Ryumachi Rheum. 1991;31:511-8.

4. Uppal SS, Pande IR, Kumar A, et al. Adult onset Still’s disease in northern India: comparison with juvenile onset Still’s disease. Br

5. J Rheumatol. 1995;34:429-34. doi: 10.1093/rheumatology/34.5.429

6. Luthi F, Zufferey P, Hofer MF, So AK. «Adolescent-onset Still’s disease»: characteristics and outcome in comparison with adult-onset Still’s disease. Clin Exp Rheumatol. 2002;20:427-30.

7. Van de Putte LB, Wouters JM. Adult-onset Still’s disease. Baillieres Clin Rheumatol. 1991;5:263-75. doi: 10.1016/S0950-3579(05)80283-3

8. Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54:587-90.

9. doi: 10.1136/ard.54.7.587

10. Kaipiainen-Seppä nen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med. 1996;240:81-4. doi: 10.1046/j.1365-2796.1996.14843000.x

11. Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol. 2006;35:48-51. doi: 10.1080/03009740510026616

12. Joung CI, Lee HS, Lee SW, et al. Association between HLADRB1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol. 2003;21:489-92.

13. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology. 2001;40:1398-404. doi: 10.1093/rheumatology/40.12.1398

14. Sampalis JS, Medsger TA Jr, Fries JF, et al. Risk factors for adult Still’s disease. J Rheumatol. 1996;23:2049-54.

15. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65:564-72. doi: 10.1136/ard.2005.042143

16. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset Still’s disease: from pathophysiology to targeted therapies. Int J Inflam. 2012;2012:879020. doi: 10.1155/2012/879020

17. Chen DY, Lan JL, Lin FJ, et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis. 2004;63:1300-6. doi: 10.1136/ard.2003.013680

18. Chen DY, Chen YM, Lan JL, et al. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology. 2010;49:2305-12. doi: 10.1093/rheumatology/keq284

19. Муравьев ЮВ, Жуковская ГН, Лебедева ВВ. О синдроме Стилла у взрослых. Ревматология. 1991;(1):37-40

20. Муравьев ЮВ, Насонов ЕЛ. Болезнь Стилла, развившаяся

21. у взрослых. Научно-практическая ревматология. 2011;49(2):58-65

22. doi: 10.14412/1995-4484-2011-604

23. Baxevanos G, Tzimas T, Pappas G, Akritidis N. A series of 22 patients with adult-onset Still’s disease presenting with fever of unknown origin. A difficult diagnosis? Clin Rheumatol. 2012;31:49-53. doi: 10.1007/s10067-011-1761-y

24. Chen PD, Yu SL, Chen S, et al. Retrospective study of 61 patients with adult-onset Still’s disease admitted with fever of unknown origin in China. Clin Rheumatol. 2012;31:175-8. doi: 10.1007/s10067-011-1798-y

25. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and longterm follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13:R91. doi: 10.1186/ar3366

26. Riera E, Olive A, Narvaez J, et al. Adult onset Still’s disease: review of 41 cases. Clin Exp Rheumatol. 2011;29:331-6.

27. Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult-onset still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29:1015-9. doi: 10.1007/s10067-010-1516-1

28. Franchini S, Dagna L, Salvo F, et al. Adult onset Still’s disease: clinical presentation in a large cohort of Italian patients. Clin Exp Rheumatol. 2010;28:41-8.

29. Lee SW, Park YB, Song JS, Lee SK. The mid-range of the adjusted level of ferritin can predict the chronic course in patients with adult onset Still’s disease. J Rheumatol. 2009;36:156-62.

30. Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol. 2009;19:57-63. doi: 10.3109/s10165-008-0126-0

31. Mehrpoor G, Owlia MB, Soleimani H, Ayatollahi J. Adult-onset Still’s disease: a report of 28 cases and review of the literature. Mod Rheumatol. 2008;18:480-5. doi: 10.3109/s10165-008-0104-6

32. Singh S, Samant R, Joshi VR. Adult onset Still’s disease: a study of 14 cases. Clin Rheumatol. 2008;27:35-9. doi: 10.1007/s10067-007-0648-4

33. Uppal SS, Al-Mutairi M, Hayat S, et al. Ten years of clinical experience with adult onset Still’s disease: is the outcome improving? Clin Rheumatol. 2007;26:1055-60. doi: 10.1007/s10067-006-0440-x

34. Pay S, Tü rkcapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639-44. doi: 10.1007/s10067-005-0138-5

35. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424-30.

36. Pouchout J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course and outcome in 62 patients. Medicine (Baltimore). 1991;70:118-36. doi: 10.1097/00005792-199103000-00004

37. Reginato AJ, Schumacher HR Jr, Baker DG, et al. Adult onset Still’s disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum. 1987;17:39-57. doi: 10.1016/0049-0172(87)90015-1

38. Bjö rkengren AG, Pathria MN, Sartoris DJ, et al. Carpal alterations in adult-onset Still disease, juvenile chronic arthritis and adult-onset rheumatoid arthritis: comparative study. Radiology. 1987;165:545-8. doi: 10.1148/radiology.165.2.3659381

39. Appenzeller S, Castro GR, Costallat LT, et al. Adult-onset Still’ disease in southeast Brazil. J Clin Rheumatol. 2005;11:76-80. doi: 10.1097/01.rhu.0000158544.38663.0a

40. Yamamoto T. Cutaneous manifestations associated with adult-onset Still’s disease: important diagnostic values. Rheumatol Int. 2012;32:2233-7. doi: 10.1007/s00296-011-2330-z

41. Nguyen KH, Weisman MH. Severe sore throat as a presenting symptom of adult onset Still’s disease: a case series and review of the literature. J Rheumatol. 1997;24:592-7.

42. Min JK, Cho CS, Kim HY, Oh EJ. Bone marrow findings in patients with adult Still’s disease. Scand J Rheumatol. 2003;32:119-21. doi: 10.1080/03009740310000148

43. Ohta A, Yamaguchi M, Kaneoka H, et al. Adult Still’s disease: review of 228 cases from the literature. J Rheumatol. 1987;14:1139-46.

44. Andres E, Kurts JE, Perrin AE, et al. Retrospective monocentric study of 17 patients with adult Still’s disease with special focus on liver abnormalities. Hepatogastroenterology. 2003;50:192-5.

45. Akritidis N, Giannakakis I, Giouglis T, et al. Ferritin levels and response to treatment in patients with Adult Still’s disease. J Rheumatol. 1996;23:201-2.

46. Fautrel B, Le Moёl G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol. 2001;28:3223.

47. Cush JJ, Medsger Jr T, Christy WC, et al. Adult-onset Still’s disease: clinical course and outcome. Arthritis Rheum. 1987;30:186-94. doi: 10.1002/art.1780300209

48. Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set ofclassification criteria for adult-onset Still disease. Medicine (Baltimore). 2002;81:194-200. doi: 10.1097/00005792-200205000-00003

49. Masson C, Le Loet X, Liote F, et al. Comparative study of 6 types of criteria in adult Still’s disease. J Rheumatol. 1996;23:495-7.

50. Wouters JM, van de Putte LB. Adult-onset Still’s disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med. 1986;61:1055-65.

51. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297.

52. doi: 10.1371/journal.pmed.0030297

53. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140:784-90. doi: 10.1016/j.cell.2010.03.002

54. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708-22.

55. doi: 10.1016/j.autrev.2014.01.058

56. Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13(11):1149-59. doi: 10.1016/j.autrev.2014.08.032

57. Canna SW. Editorial. Interferon-: friend or foe in systemic juvenile idiopathic arthritis and adult Still’s disease. Arthritis Rheum. 2014;66:1072-6. doi: 10.1002/art.38362

58. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61:345-8. doi: 10.1016/j.cyto.2012.11.025

59. Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189-98.

60. Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of adult-onset Still’s disease presenting with erosive arthritis: association with low levels of ferritin and IL-18. Arthritis Care Res (Hoboken). 2013 Oct 7. [Epub ahead of print].

61. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. 2010;49:1645-53. doi: 10.1093/rheumatology/keq133

62. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91-9. doi: 10.1097/MD.0000000000000021

63. Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530-5. doi: 10.1002/art.27532

64. Kim YJ, Koo BS, Kim Y-G, et al. Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol. 2014;32:28-33.

65. Hot A, Toh M-L, Coppere B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and longterm outcome: a case-control study of 8 patients. Medicine (Baltimore). 2010;89:37-46. doi: 10.1097/MD.0b013e3181caf100

66. Nagashima T, Iwamoto M, Matsumoto K, Minota S. Interleukin-18 in adult-onset Still’s disease: treatment target or disease activity indicator? Intern Med. 2012;51:449.

67. doi: 10.2169/internalmedicine.51.6678

68. Kim H-A, Sung J-M, Suh C-H. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291-8. doi: 10.1007/s00296-011-1801-6

69. Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373-8.

70. Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295-8.

71. Permal S, Wechsler B, Cabane J, et al. [Treatment of Still’s disease in adults with intravenous immunoglobulins]. Rev Med Interne. 1995;16:250-4. doi: 10.1016/0248-8663(96)80703-X

72. Муравьев ЮВ. Применение генно-инженерных биологиче-ских препаратов при болезни Стилла, развившейся у взрос-лых. В кн.: Насонов ЕЛ, редактор. Генно-инженерные биоло-гические препараты в лечении ревматоидного артрита. Моск-ва: ИМА-ПРЕСС; 2013. С. 398-404

73. Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report. Clin Exp Rheumatol. 2005;23:733.

74. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.

75. doi: 10.1002/art.1780380602

76. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46:1171-6. doi: 10.1002/art.10231

77. Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329-32.

78. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60 Suppl 3:iii55-7.

79. Kokkinos A, Iliopoulos A, Greka P, et al. Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004;23:45-9. doi: 10.1007/s10067-003-0775-5

80. Fautrel B, Sibilia J, Mariette X, Combe B; Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262-6. doi: 10.1136/ard.2004.024026

81. Aikawa NE, Ribeiro AC, Saad CG, et al. Is anti-TNF switching in refractory Still’s disease safe and effective? Clin Rheumatol. 2011;30:1129-34. doi: 10.1007/s10067-011-1735-0

82. Kaneko K, Kaburaki M, Muraoka S, et al. Exacerbation of adult-onset Still’s disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010;13:e67-9. doi: 10.1111/j.1756-185X.2010.01544.x

83. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis. 2005;64:647-8. doi: 10.1136/ard.2004.026617

84. Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794-803. doi: 10.1002/art.21061

85. Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842-3. doi: 10.1136/ard.2006.066381

86. Kö tter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189-97. doi: 10.1016/j.semarthrit.2007.04.002

87. Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset Still disease with anakinra. J Clin Rheumatol. 2003;9:330-2. doi: 10.1097/01.rhu.0000089966.48691.7f

88. Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset Still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376-7. doi: 10.1016/j.jbspin.2013.12.011

89. Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42:201-5. doi: 10.1016/j.semarthrit.2012.03.004

90. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557-67. doi: 10.1002/art.33342

91. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396-406. doi: 10.1056/NEJMoa1205099

92. Puechal X, DeBandt M, Berthelot J-M, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63:155-9. doi: 10.1002/acr.20319

93. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49-55. doi: 10.1007/s10067-013-2381-5

94. Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244-7. doi: 10.3899/jrheum.130881

95. Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheum. 2014;66:1659-65. doi: 10.1002/art.38398

96. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis. 2006;65:1117-8. doi: 10.1136/ard.2005.047621

97. Arlet J-B, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596-601.

98. doi: 10.1136/ard.2005.046904

99. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289-98. doi: 10.1038/gene.2012.3

100. Silva CA, Silva CH, Robazzi TC, et al. [Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis]. J Pediatr (Rio J). 2004;80:517-22. doi: 10.2223/1267

101. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401-3.

102. Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit. 2008;14:RA27-36.

103. Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305-14. doi: 10.1007/s10067-014-2487-4

104. Mizrahi M, Ben-Chetrit E. Relapsing macrophage activating syndrome in a 15-year-old girl with Still’s disease: a case report.J Med Case Rep. 2009;3:138. doi: 10.1186/1752-1947-3-138

105. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615-20. doi: 10.1038/ncprheum0919

106. Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17:23-7.

107. doi: 10.1097/RHU.0b013e318205092d

108. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38:180-1. doi: 10.3899/jrheum.100726

109. Pamuk ON, Pamuk GE, Usta U, Cakir N. Hemophagocytic syndrome in one patient with adult-onset Still’s disease. Presentation with febrile neutropenia. Clin Rheumatol. 2007;26:797-800.

110. doi: 10.1007/s10067-006-0238-x

111. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252-6. doi: 10.1097/00124743-200108000-00013

112. Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92-6. doi: 10.3109/s10165-010-0348-9

113. Aellen P, Raccaud O, Waldburger M, et al. [Still’s disease in adults with disseminated intravascular coagulation]. Schweiz Rundsch Med Prax. 1991;80:376-8.

114. Arai Y, Handa T, Mitani K. [Adult-onset Still disease presenting with disseminated intravascular coagulation]. Rinsho Ketsueki. 2004;45:316-8.

115. Рark J-H, Bae JH, Choi Y-S, et al. Adult-onset Still’s disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A. J Korean Med Sci. 2004;19:137-41. doi: 10.3346/jkms.2004.19.1.137

116. Yokoyama M, Suwa A, Shinozawa T, et al. [A case of adult onset

117. Still’s disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation]. Nihon Rinsho Meneki Gakkai Kaishi. 1995;18:207-14. doi: 10.2177/jsci.18.207

118. Mori T, Tanigawa M, Iwasaki E, et al. [Cyclosporine therapy of adult onset Still’s disease with disseminated intravascular coagulation]. Nihon Rinsho Meneki Gakkai Kaishi. 1993;34:147-52.

119. Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28:485-7.

120. doi: 10.1007/s10067-009-1097-z

121. Gerfaud-Valentin M, Seve P, Iwaz J, et al. Myocarditis in adult-onset Still disease. Medicine (Baltimore). 2014;93:280-9. doi: 10.1097/MD.0000000000000112

122. Perez MG, Rodwig FR Jr. Chronic relapsing thrombotic thrombocytopenic purpura in adult onset Still’s disease. South Med J. 2003;96:46-9. doi: 10.1097/01.SMJ.0000047763.56451.F0

123. Masuyama A, Kobayashi H, Kobayashi Y, et al. A case of adult-onset Still’s disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema. Mod Rheumatol. 2013;23:379-85. doi: 10.3109/s10165-012-0650-9

124. Sayarlioglu M, Sayarlioglu H, Ozkaya M, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and adult onset Still’s disease: case report and review of the literature. Mod Rheumatol. 2008;18,403-6. doi: 10.3109/s10165-008-0061-0

125. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med. 1992;152:791-6. doi: 10.1001/archinte.1992.00400160089017

126. Cheema GS, Quismorio FP. Pulmonary involvement in adult-onset Still’s disease. Curr Opin Pulm Med. 1999;5:305-9.

127. doi: 10.1097/00063198-199909000-00007

128. Sari I, Birlik M, Binicier O, et al. A case of adult-onset Still’s disease complicated with diffuse alveolar hemorrhage. J Korean Med Sci. 2009;24:155-7. doi: 10.3346/jkms.2009.24.1.155

129. Gerfaud-Valentin M, Hot A, Huissoud C, et al. Adult-onsetStill’s disease and pregnancy: about ten cases and review of the literature. Rheumatol Int. 2014;34:867-71. doi: 10.1007/s00296-013-2765-5

130. Le Loёt X, Daragon A, Duval C, et al. Adult onset Still’s disease and pregnancy. J Rheumatol. 1993;20:1158-61.

131. Lockshin MD, Sammaritano LR. Corticosteroids during pregnancy. Scand J Rheumatol. 1998;107 Suppl:136-8.

132. doi: 10.1080/03009742.1998.11720789

133. Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol. 2011;29:1021-3.

134. Berger CT, Recher M, Steiner U, Hauser TM. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68:1794-5. doi: 10.1136/ard.2008.105833


Для цитирования:


Лебедева В.В., Муравьев Ю.В. Особенности болезни Стилла, развившейся у взрослых, в XXI в. Научно-практическая ревматология. 2018;56(4):506-514. https://doi.org/10.14412/1995-4484-2018-506-514

For citation:


Lebedeva V.V., Muravyev Y.V. CHARACTERISTICS OF ADULT-ONSET STILL’S DISEASE IN THE 21ST CENTURY Rheumatology Science and Practice. 2018;56(4):506-514. (In Russ.) https://doi.org/10.14412/1995-4484-2018-506-514

Просмотров: 200


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)